The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever

Background Autologous stem cell transplantation (ASCT) remains the standard of care for young multiple myeloma (MM) patients; indeed, at-home ASCT has been positioned as an appropriate therapeutic strategy. However, despite the use of prophylactic antibiotics, neutropenic fever (NF) and hospital readmissions continue to pose as the most important limitations in the outpatient setting. It is possible that the febrile episodes may have a non-infectious etiology, and engraftment syndrome could play a more significant role. The aim of this study was to analyze the impact of both G-CSF withdrawal and the addition of primary prophylaxis with corticosteroids after ASCT. Methods Between January 2002 and August 2018, 111 MM patients conditioned with melphalan were managed at-home beginning +1 day after ASCT. Three groups were established: Group A (n = 33) received standard G-CSF post-ASCT; group B (n = 32) avoided G-CSF post-ASCT; group C (n = 46) avoided G-CSF yet added corticosteroid prophylaxis post-ASCT. Results The incidence of NF among the groups was reduced (64%, 44%, and 24%; P<0.001), with a non-significant decrease in hospital readmissions as well (12%, 6%, and 2%; P = 0.07). The most important variables identified for NF were: HCT-CI >2 (OR 6.1; P = 0.002) and G-CSF avoidance plus corticosteroids (OR 0.1; P<0.001); and for hospital readmission: age ≥60 years (OR 14.6; P = 0.04) and G-CSF avoidance plus corticosteroids (OR 0.07; P = 0.05). Conclusions G-CSF avoidance and corticosteroid prophylaxis post ASCT minimize the incidence of NF in MM patients undergoing at-home ASCT. This approach should be explored in a prospective randomized clinical trial.

[1]  G. Gutiérrez-García,et al.  Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients , 2020, Leukemia & lymphoma.

[2]  G. Gutiérrez-García,et al.  A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe , 2020, Bone Marrow Transplantation.

[3]  María Teresa Solano,et al.  Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis , 2019, Bone Marrow Transplantation.

[4]  G. Gutiérrez-García,et al.  Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation , 2018, Bone Marrow Transplantation.

[5]  R. Greil,et al.  The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe , 2018, Expert review of hematology.

[6]  H. Goldschmidt,et al.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Goldschmidt,et al.  High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting , 2017, BMC Cancer.

[8]  D. Giannarelli,et al.  Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study , 2017, Bone Marrow Transplantation.

[9]  L. Castagna,et al.  Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma , 2016, Bone Marrow Transplantation.

[10]  G. Gutiérrez-García,et al.  At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study , 2016, Bone Marrow Transplantation.

[11]  P. Hari,et al.  Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  S. Crawford,et al.  Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  T. Walsh,et al.  Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  D. Porter,et al.  Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. , 2015, Clinical lymphoma, myeloma & leukemia.

[15]  A. Gennery,et al.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015 , 2015, Bone Marrow Transplantation.

[16]  P. Hari,et al.  Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma , 2015, Bone Marrow Transplantation.

[17]  M. Postorino,et al.  A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study , 2015, Leukemia & lymphoma.

[18]  R. Gale,et al.  Engraftment syndrome, the Emperor’s new clothes and the artist formerly known as prince , 2015, Bone Marrow Transplantation.

[19]  T. Spitzer,et al.  Engraftment syndrome: double-edged sword of hematopoietic cell transplants , 2015, Bone Marrow Transplantation.

[20]  A. López-Guillermo,et al.  Survival analysis in hematologic malignancies: recommendations for clinicians , 2014, Haematologica.

[21]  M. Dimopoulos,et al.  International Myeloma Working Group recommendations for global myeloma care , 2014, Leukemia.

[22]  H. Heslop,et al.  Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma , 2013, Bone Marrow Transplantation.

[23]  M. Sanz,et al.  Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients , 2014, Annals of Hematology.

[24]  P. Hari,et al.  Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  Stephanie J. Lee,et al.  Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  G. Sauvageau,et al.  Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  W. Dempke,et al.  Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysis. , 2012, Anticancer research.

[28]  B. Esterni,et al.  Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs , 2012, Bone Marrow Transplantation.

[29]  M. Díaz-Ricart,et al.  Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.

[30]  D. Dingli,et al.  SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization , 2011, Bone Marrow Transplantation.

[31]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  M. Dimopoulos,et al.  Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem‐cell transplantation: Results of a single institution, randomized phase 2 trial , 2010, American journal of hematology.

[33]  F. Aversa,et al.  Regression modeling of competing risk using R: an in depth guide for clinicians , 2010, Bone Marrow Transplantation.

[34]  M. Díaz-Ricart,et al.  Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  M. Lozano,et al.  Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center , 2010, Bone Marrow Transplantation.

[36]  Hermann Einsele,et al.  Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.

[37]  M. Díaz-Ricart,et al.  The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  D. Dingli,et al.  Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome , 2008, European journal of haematology.

[39]  F. Aversa,et al.  Competing risk analysis using R: an easy guide for clinicians , 2007, Bone Marrow Transplantation.

[40]  E. Montserrat,et al.  Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Solano,et al.  Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fluoroquinolones and intravenous piperacillin–tazobactam , 2005, Bone Marrow Transplantation.

[42]  L. Rybicki,et al.  Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection , 2005, Bone Marrow Transplantation.

[43]  Â. Maiolino,et al.  Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria , 2003, Bone Marrow Transplantation.

[44]  P. Mcsweeney,et al.  High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[45]  T. Spitzer Engraftment syndrome following hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.